The Daratumumab Or Darzalex Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The daratumumab or darzalex market has seen quick growth recently. This market is projected to expand from a value of $5,093.04 million in 2024 to $5,618.30 million in 2025. This growth corresponds to a compound annual growth rate (CAGR) of 10.3%.
The Daratumumab or Darzalex market is forecasted to reach a size of $8,189.36 million in 2029, expanding at a compound annual growth rate (CAGR) of 10.0%.
Download Your Free Sample of the 2025 Daratumumab Or Darzalex Market Report and Uncover Key Trends Now!The key drivers in the daratumumab or darzalex market are:
• Increased incidence of bone marrow cancer due to aging population and improved detection methods.
• Use of daratumumab (Darzalex) in the treatment of multiple myeloma, a type of bone marrow cancer.
• Growing adoption of targeted therapies and biologics in treating various diseases.
• The specific action of daratumumab on CD38 protein on the surface of malignant plasma cells in multiple myeloma.
The daratumumab or darzalex market covered in this report is segmented –
1) By Drug Type: 100Mg Injection, 400Mg Injection
2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels
3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications
The key trends in the daratumumab or darzalex market are:
• Increased adoption in transplantation is a notable emerging trend.
• Regional variability in demand is influencing market dynamics.
• Advancements in biotechnology are shaping the future of the market.
• The growing immunocompromised population is driving innovation.
Major players in the daratumumab or darzalex market are:
• Genmab A/S
• Janssen Biotech Inc.
The North America region leads the global Daratumumab Or Darzalex market as of 2024.